<DOC>
	<DOC>NCT00996606</DOC>
	<brief_summary>This open-label, single-arm study will evaluate the efficacy and safety of tocilizumab in combination with DMARDs in participants with moderate to severe active rheumatoid arthritis who have an inadequate response to DMARDs. Participants will receive tocilizumab as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion every 4 weeks in addition to their current DMARD therapy.</brief_summary>
	<brief_title>A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Moderate to severe active RA of ≥6 months duration DAS28 &gt;3.2 Inadequate response to a stable dose of nonbiologic DMARD for ≥2 months Those receiving oral corticosteroids must have been at stable dose for ≥25 days in the 28 days prior to first study treatment Rheumatic autoimmune disease other than RA History of or current inflammatory joint disease other than RA Previous treatment with alkylating agents or total lymphoid irradiation Intraarticular or parenteral corticosteroids within 6 weeks prior to Baseline Previous treatment with any celldepleting therapies American College of Rheumatology (ACR) Functional Class IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>